Navigation Links
Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
Date:3/12/2008

o shown clinical activity in a range of skeletal diseases, including bone metastasis, Paget's disease and osteoporosis. An oral dosing regimen offers the potential to exploit the advantages of this compound, which include broad potential activity and convenient administration.

Tesetaxel

Tesetaxel, an oral taxane that is the latest addition to the Genta oncology portfolio, was recently obtained via in-licensing of its worldwide rights. Tesetaxel was specifically developed to avoid key problems associated with other taxanes (such as paclitaxel [Taxol(R); Bristol Myers Squibb] and docetaxel [Taxotere(R); sanofi Aventis]), including severe infusion reactions, peripheral neuropathy, and acquired drug resistance. More than 250 patients worldwide have received tesetaxel, and the drug has demonstrated anticancer activity in several clinical trials. Due to the occurrence of several fatalities related to neutropenia, the drug is currently on clinical hold in the U.S. Based upon guidance from FDA, Genta has worked with the former sponsor to develop a strategy that is intended to lift the clinical hold, thereby enabling clinical testing to resume. If further studies document efficacy and safety, tesetaxel offers substantial opportunities to improve convenience, safety, and activity for patients who are currently receiving conventional taxanes.

C-myb Antisense

An antisense drug directed against c-myb, a master regulatory proto- oncogene, is the Company's earliest stage clinical program. In 2007, a new dose-ranging Phase 1 trial of c-myb antisense was initiated at the University of Pennsylvania. The trial is currently open to accrual and is expected to be completed later this year after identification of the MTD.

Financial Information

The Company reported a net loss of $1.7 million or $0.06 per share for the fourth quarter of 2007, compared with a net loss of $17.3 million or $0.68 per share for the fourth quarter of 2006. For the year en
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
2. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
3. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
4. Genta Clinical Programs Featured at American Society of Hematology Meeting
5. Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases
6. Genta Incorporated Announces Third Quarter 2007 Financial Results
7. Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease
8. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
11. Inclinix Announces New Patent for Expert System Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... -- AVACEN Medical announced today that its AVACEN 100 ... by the U.S. Food and Drug Administration. This clearance ... Internet for: the temporary relief of joint pain ... sprains . Logo - http://photos.prnewswire.com/prnh/20141021/153513 ... a sophisticated medical device incorporating over 3,000 firmware instructions ...
(Date:10/22/2014)...   BioNano Genomics , the genome mapping ... to purchase an Irys™ System . Among them ... (NCI), NIH Intramural Sequencing Center (NISC) and Genoscope (The ... comprehensive view of a genome was a major ... deliver the scalability or reliability to detect and ...
(Date:10/22/2014)... , Oct. 22, 2014 InVivo Therapeutics ... MA is revolutionizing spinal cord injury (SCI) ... been shown to outperform in tissue regrowth in the ... scaffold.  Made from an FDA approved polymer, the scaffold ... it harmless to the human body. NVIV has recently ...
Breaking Medicine Technology:AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3
... Oct. 8 Pioneer Surgical Technology, Inc. and SpineSmith, ... Pioneer Surgical will acquire exclusive rights to manufacture and ... the agreement, Pioneer Surgical will become the manufacturer of ... sales network, while adding SpineSmith as a distributor.  "We ...
... Md., Oct. 8 Abbott Laboratories has agreed ... from the U.S. market because of clinical trial ... and stroke, the U.S. Food and Drug Administration ... ) (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) ...
Cached Medicine Technology:Pioneer® Surgical Technology, Inc. Announces Agreement to Acquire Exclusive Access to the Cequence™ Cervical Plate System From SpineSmith, LP 2Abbott Laboratories Agrees to Withdraw Its Obesity Drug Meridia 2
(Date:10/22/2014)... 22, 2014 On October 22, CBS ... featuring skin diseases both fictional and real. The ... nonprofit organization committed to advocacy and philanthropy in the ... take the opportunity to impart truth and clarity about ... There are many misconceptions about Morgellons Disease ...
(Date:10/22/2014)... Amy Norton HealthDay ... Headlines remain riveted on the three Ebola cases in Dallas. ... bigger health threat to Americans. President Barack Obama on ... to the virus, which has infected two Dallas nurses who ... month at Texas Health Presbyterian Hospital. But the U.S. ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Hay House is ... Beyond Addiction and Upgrade Your Life (Paperback; $10.82) written by ... Yoga & Recovery. This book is meant to help ... a life of recovery. , Recovery 2.0 is not ... Steps; Recovery 2.0 is a guide for what comes next. ...
(Date:10/22/2014)... 22, 2014 Healthcare professionals who ... continuing education at home or on-the-go via laptops, ... 20 brand new, premium Seminar-on-Demand CE courses. The ... over 2,000 hours of CE course ... educational experience. With such a diverse library, there’s ...
(Date:10/22/2014)... 2014 Richard Carlson, Managing Partner of ... with over 25 years experience. Mr. Carlson is ... areas related to EDI, B2B Commerce, RFID and Internet/Intranet ... Advisory Board member for Pharmaceutical Commerce Magazine and a ... Group is a management and technology consulting firm focused ...
Breaking Medicine News(10 mins):Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2
... so that,s what she pursued as a career. But she always ... some cardiologists at a party, she started talking with them about ... we could provide them with a fluid dynamics and mechanics point ... stent grafts they use in their procedures," she says. Stents ...
... sledding is a popular winter pastime, it can unfortunately ... the Center for Injury Research and Policy of The ... 1997-2007, an estimated 229,023 children and adolescents younger than ... for sledding-related injuries an average of more than ...
... found that while colon cancer rates have remained steady over ... 40, rectal cancer rates are increasing in this population across ... Cancer , a peer-reviewed journal of the American Cancer Society, ... rectal cancer in young individuals who show potential signs of ...
... 2010) -- A signaling protein released during rheumatoid arthritis ... impairment of mice bred to develop symptoms of the ... South Florida reports. Researchers found that the protein, ... attack and remove Alzheimer,s amyloid deposits in the brain. ...
... the nation,s largest general hospitals appeared to have a ... (RTAT), improving patient care, according to a study in ... Roentgenology ( www.ajronline.org ). One increasingly ... and Medicare Services and by third-party payers, attempts to ...
... the medical community has already accepted that colorectal cancer ... have found that computed tomography colonography (CTC or virtual ... yield of identifying significant early extracolonic (outside the colon) ... in the September issue of the American Journal of ...
Cached Medicine News:Health News:Math from the heart: Simulating stent design and coating 2Health News:Math from the heart: Simulating stent design and coating 3Health News:New study: More than 20,000 sledding injuries each year 2Health News:Rectal cancer rates are rising in young individuals 2Health News:Rheumatoid arthritis signaling protein reverses Alzheimer's disease in mouse model 2Health News:Rheumatoid arthritis signaling protein reverses Alzheimer's disease in mouse model 3Health News:Pay-for-performance programs improve radiology report turnaround times, study suggests 2
... special order products are offered as 1-piece ... lengths. The modular instruments may be customized ... such as ratchets, insulation and flush ports. ... stock. Customer specifications may affect delivery times. ...
... The Featured Products are ... Mediflex and are offered ... in regular or extra ... equipped with insulation, flush ...
... The Featured Products are ... Mediflex and are offered ... in regular or extra ... equipped with insulation, flush ...
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
Medicine Products: